💊 الأدوية من أ إلى ي 🧬 الأهداف 🛠 الأدوات 📚 الأدلة
جميع الأدوية تصنيفات الأدوية المجالات العلاجية الآثار الجانبية
الأدلة المسرد الجدول الزمني
المقارنات مسارات الأدوية عائلات الأدوية
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Agomelatine

CHEMBL10878 Phase 4 معتمد Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
243.3 g/mol
LogP
2.7
Phase
4

An antidepressant that works differently from most other medications by activating melatonin receptors and blocking certain serotonin receptors, helping to restore normal sleep-wake cycles that are often disrupted in depression and anxiety. It improves mood, reduces anxiety, and supports better sleep without the sexual side effects commonly associated with other antidepressants.

الوزن الجزيئي

243,3000 g/mol

LogP

2,70

TPSA

38,30 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Schizophrenia Generalized Anxiety Disorder Stroke Major Depressive Disorder

آلية العمل

Activates melatonin MT1 and/or MT2 receptors in the suprachiasmatic nucleus, resetting circadian rhythm timing and promoting sleep onset.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Activates melatonin MT1 and/or MT2 receptors in the suprachiasmatic nucleus, resetting circadian rhythm timing and promoting sleep onset.

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1ccc2cccc(CCNC(C)=O)c2c1

                

                

                
                

                    
InChI

                    
InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)

                

                

                

                    
                    

                        
Molecular Formula

                        
C15H17NO2

                    

                    
                    

                        
HBD / HBA

                        
1 / 2

                    

                    
                    

                        
الروابط القابلة للدوران

                        
4

                    

                    
                    
                    

                        
الذرات الثقيلة

                        
18

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
الأسئلة الشائعة

                

                    
                    

                        
                        

                            
An antidepressant that works differently from most other medications by activating melatonin receptors and blocking certain serotonin receptors, helping to restore normal sleep-wake cycles that are often disrupted in depression and anxiety. It improves mood, reduces anxiety, and supports better sleep without the sexual side effects commonly associated with other antidepressants.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Activates melatonin MT1 and/or MT2 receptors in the suprachiasmatic nucleus, resetting circadian rhythm timing and promoting sleep onset.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Agomelatine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL10878.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 82148.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
إخلاء المسؤولية الطبية

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.